Migraine | Disease Landscape & Forecast | G7 | 2021
Migraine, which afflicts approximately 34 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s symptoms and needs, headache pattern, comorbidities, contraindications, and treatment history. With the launch of newer migraine-specific treatment alternatives (e.g., anti-CGRP MAbs for migraine prevention, gepants for the treatment of acute migraine attacks) and more on the near-term horizon, brand choice is rapidly expanding in this heavily generic market. Understanding the intersecting forces of unmet need, cost / coverage, and the availability of many low-cost, early-line SOCs will be key to the success of current and future players in migraine.
Questions Answered:
- What events will shape the future of the acute and preventive market segments?
- How will the anti-CGRP MAbs and gepants impact the migraine prophylaxis market? Which brands will be the most competitive and why?
- What is the dynamic between Reyvow, Ubrelvy, and Nurtec ODT? How have they been integrated into the triptan-dominant acute segment?
- How will novel reformulations compete for patient share with existing options in the niche segment of patients who need non-oral alternatives?
Product Description:
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement:
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
